Medicine Can be Sweet

  • ChemPubSoc Europe Logo
  • Author: Claire D'Andola
  • Published Date: 18 October 2013
  • Source / Publisher: Chemistry – A European Journal/Wiley-VCH
  • Copyright: Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
thumbnail image: Medicine Can be Sweet

Related Societies

Pramlintide (Symlin), a synthetic version of amylin, is a 37-amino acid peptide that is co-secreted with insulin by pancreatic β-cells. It was developed and approved in 2005 by the FDA for use in US patients with type I and II diabetes in conjunction with the administration of prandial insulin to improve postprandial glycemic control. Pramlintide, however, still has significant limitations, typical of other peptide drugs. These include low circulatory half-life and poor solubility/bioavailability. This means that it currently has to be administered as a separate injection to insulin. Glycosylation of several synthetic peptides relevant to the treatment of diabetes has been attempted to improve their pharmacokinetic properties, including insulin, GLP-1, and exendin-4. Glycosylation of amylin or amylin analogues, such as pramlintide may, therefore, be expected to produce glycopeptides with superior properties.


Antony J. Fairbanks and co-workers, University of Canterbury, New Zealand, have synthesized glycosylated analogues of pramlintide, by a combination of solid-phase peptide synthesis and highly efficient enzymatic glycosylation.


The synthetic peptides displayed both in vitro and in vivo activity as amylin receptor agonists. They were similar in moderating the rise in blood glucose during an oral glucose tolerance test (OGTT) in Sprague Dawley (SD) rats. The effects of glycosylation on other pharmacokinetic properties of these peptides are currently in progress and such studies may produce glycopeptide materials that display advantageous properties relative to pramlintide, and which may, therefore, find clinical application for the treatment of type I and II diabetes in conjunction with insulin.


Article Views: 3940

Sign in Area

Please sign in below

Additional Sign In options

Please note that to comment on an article you must be registered and logged in.
Registration is for free, you may already be registered to receive, e.g., the newsletter. When you register on this website, please ensure you view our terms and conditions. All comments are subject to moderation.

Article Comments - To add a comment please sign in

Bookmark and Share

If you would like to reuse any content, in print or online, from ChemistryViews.org, please contact us first for permission. more


CONNECT:

ChemistryViews.org on Facebook

ChemistryViews.org on Twitter ChemistryViews.org on YouTube ChemistryViews.org on LinkedIn Sign up for our free newsletter


A product of ChemPubSoc Europe (16 European Chemical Societies)and Wiley-VCH